Who would have thought that after 30 years of no new therapies that urothelial carcinomas would suddenly be almost constantly in the spotlight with enticing words like cancer immunotherapy, biomarkers, tumour microenvironment, translational immunology etc?
And yet it has happened – with a lot more to come in this highly competitive niche too.
Prior to AACR in Chicago, we highlighted TGFβ in our Preview series as an important emerging target that is gathering attention and may be relevant in tumour types, such as urothelial carcinoma and ovarian cancer.
After the meeting, Dr Paul Rennert (CSO, Aleta Biotherapeutics) noted:
2 Key messages out of #AACR18 –
Innate immune agents could save the IO combo game
You best be thinking about TGFbeta https://t.co/388ffcfoS7
— Paul D. Rennert (@PDRennert) April 18, 2018
I don’t disagree with either of these sentiments – there was a reason we interviewed a lot of NK cell enthusiasts recently and we have since been rolling out our thought leader mini-series focused on TGFβ. Yesterday, we kicked off with perspectives from an academic researcher active in this field and tomorrow will showcase some practical clinical perspectives.
On deck today, we have a interview with a research scientist who has conducted both basic and translational work for a discussion about how he sees the learnings that have arisen from bench to bedside and back again.